The Food and Drug Administration's New Drug Application is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. From Wikipedia
Phase-3 results demonstrated a 20% higher cure rate over meropenem with forecasts valuing the drug at $9 billion globally
